PTN · Palatin Technologies Inc
$11.80
-0.22 (-1.83%)
At close · Sep 11
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company's ability to meet its obligations for the next year.”View the 10-Q filed May 13, 2026
Market Cap
$21.00M
Shares
1.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.80
Open$11.82
Day$11.40–12.57
52W close$5.75–28.00
Avg vol 30d79K
Short int345K · 19.4% float · 6.7d
Short vol54%
Last earningsMay 13, 2026
DataAug 2025–Sep 2026
Filing10-Q · May 13
Raw chart and full-history price indicators begin at the captured split on Aug 12, 2025; bars on opposite sides are not compared.
Up next
Next earnings call
Sep 28, 2026
Est · unconfirmed
· in 2 wks
filed May 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$6.25M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
3.2
Trailing earnings · reciprocal yield 30.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+642.5%
Year over year · more shares
Price change (1Y)
+37.4%
Trailing year
Short interest
19.4%
Latest settlement · 6.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
+22%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
27%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
−45%
trailing
YTD return
−23%
this year
Relative strength
−63%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $16 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.42% of float · ▼ -1.1% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Squeeze score
84
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+68%
Y/Y
Free cash flow
$-21.3M
Quant / Vol
risk profile
Volatility
135%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
10.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
+22%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
27%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $10 › 200d $16 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.42% of float · ▼ -1.1% MoM · 6.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $12 · 27%
Range high $28
vs 200-day avg -26%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTN
this stock
Palatin Technologies Inc
|
$21.00M | -23.3% | -100.0% | — | 19.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 12, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTN | -9.8% | +18.0% | -45.0% | +18.1% | -23.3% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -8.6% | +19.8% | -62.8% | +18.5% | -35.4% |